HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B.

Abstract
We focused on determining the most accurate and convenient genotyping methods and most appropriate single nucleotide polymorphism (SNP) among four such polymorphisms associated with interleukin-28B (IL-28B) in order to design tailor-made therapy for patients with chronic hepatitis C virus (HCV) patients. First, five different methods (direct sequencing, high-resolution melting analysis [HRM], hybridization probe [HP], the InvaderPlus assay [Invader], and the TaqMan SNP genotyping assay [TaqMan]) were developed for genotyping four SNPs (rs11881222, rs8103142, rs8099917, and rs12979860) associated with IL-28B, and their accuracies were compared for 292 Japanese patients. Next, the four SNPs associated with IL-28B were genotyped by Invader for 416 additional Japanese patients, and the response to pegylated interferon/ribavirin (PEG-IFN/RBV) treatment was evaluated when the four SNPs were not in linkage disequilibrium (LD). HRM failed to genotype one of the four SNPs in five patients. In 2 of 287 patients, the results of genotyping rs8099917 by direct sequencing differed from the results of the other three methods. The HP, TaqMan, and Invader methods were accurate for determination of the SNPs associated with IL-28B. In 10 of the 708 (1.4%) patients, the four SNPs were not in LD. Eight of nine (88.9%) patients whose rs8099917 was homozygous for the major allele were virological responders, even though one or more of the other SNPs were heterozygous. The HP, TaqMan, and Invader methods were suitable to determine the SNPs associated with IL-28B. The rs8099917 polymorphism should be the best predictor for the response to the PEG-IFN/RBV treatment among Japanese chronic hepatitis C patients.
AuthorsKiyoaki Ito, Katsuya Higami, Naohiko Masaki, Masaya Sugiyama, Motokazu Mukaide, Hiroaki Saito, Yoshihiko Aoki, Yo Sato, Masatoshi Imamura, Kazumoto Murata, Hideyuki Nomura, Shuhei Hige, Hiroshi Adachi, Keisuke Hino, Hiroshi Yatsuhashi, Etsuro Orito, Satomi Kani, Yasuhito Tanaka, Masashi Mizokami
JournalJournal of clinical microbiology (J Clin Microbiol) Vol. 49 Issue 5 Pg. 1853-60 (May 2011) ISSN: 1098-660X [Electronic] United States
PMID21389156 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antiviral Agents
  • interferon-lambda, human
  • Interferon-alpha
  • Interleukins
  • Ribavirin
  • Interferons
Topics
  • Aged
  • Antiviral Agents (administration & dosage)
  • Asian People
  • Drug Therapy, Combination (methods)
  • Female
  • Genetic Testing (methods)
  • Genotype
  • Hepatitis C, Chronic (drug therapy)
  • Humans
  • Interferon-alpha (administration & dosage)
  • Interferons
  • Interleukins (genetics)
  • Japan
  • Male
  • Middle Aged
  • Polymorphism, Single Nucleotide
  • Prognosis
  • Ribavirin (administration & dosage)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: